Natixis Advisors LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Natixis Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 5.7%, owning 116,232 shares worth approximately $73.7 million as of its latest filing.
• Regeneron reported $8.22 earnings per share for Q1, which missed analyst expectations, with revenues of $3.03 billion compared to a forecast of $3.40 billion.
• The company has a dividend yield of 0.63%, having declared a quarterly dividend of $0.88 per share, showing a payout ratio of 8.96%.

Natixis Advisors LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 116,232 shares of the biopharmaceutical company's stock after acquiring an additional 6,294 shares during the quarter. Natixis Advisors LLC owned approximately 0.11% of Regeneron Pharmaceuticals worth $73,718,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $32,000. Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $32,000. Finally, American National Bank & Trust purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $44,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 2.5%

Regeneron Pharmaceuticals stock traded up $13.41 during mid-day trading on Friday, hitting $558.87. The company had a trading volume of 1,656,418 shares, compared to its average volume of 858,977. The stock has a market cap of $60.34 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 2.05 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $538.05 and a 200 day moving average of $604.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $9.55 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Bank of America dropped their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a report on Friday. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. Finally, Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $837.61.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.